Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTRM-555 Triple Combination in Relapsed/Refractory Lymphoma
NCT04305444Phase 2Terminated
- Sponsor
- DTRM Biopharma
- Start
- Apr 2020
- Primary completion
- Dec 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Multivalent & Scaffold-Based Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of DTRMWXHS-12 in chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 1 more, sponsored by DTRM Biopharma. Primary endpoints: Complete Response at 24 months and Partial Response at 24 months. Started Apr 2020; status: terminated.
02
Drugs
DTRMWXHS-12
03
Conditions
chronic lymphocytic leukemia (CLL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)Richter's transformation (RT)
Beyond the preview
Go deeper on NCT04305444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305444.